Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | LONP1 | P36776 | 5/20 | 0.48 |
| ▸ | PSMB11 | A5LHX3 | 4/20 | 0.48 |
| ▸ | PSMA7 | O14818 | 4/20 | 0.48 |
| ▸ | PSMB1 | P20618 | 4/20 | 0.48 |
| ▸ | PSMA1 | P25786 | 4/20 | 0.48 |
| ▸ | PSMA2 | P25787 | 4/20 | 0.48 |
| ▸ | PSMA3 | P25788 | 4/20 | 0.48 |
| ▸ | PSMA4 | P25789 | 4/20 | 0.48 |
| ▸ | PSMB8 | P28062 | 4/20 | 0.48 |
| ▸ | PSMB9 | P28065 | 4/20 | 0.48 |
| ▸ | PSMA5 | P28066 | 4/20 | 0.48 |
| ▸ | PSMB4 | P28070 | 4/20 | 0.48 |
| ▸ | PSMB6 | P28072 | 4/20 | 0.48 |
| ▸ | PSMB5 | P28074 | 4/20 | 0.48 |
| ▸ | PSMB10 | P40306 | 4/20 | 0.48 |
| ▸ | PSMB3 | P49720 | 4/20 | 0.48 |
| ▸ | PSMB2 | P49721 | 4/20 | 0.48 |
| ▸ | PSMA6 | P60900 | 4/20 | 0.48 |
| ▸ | PSMA8 | Q8TAA3 | 4/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319446 | 1.00 | MAPT (0.51) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL8033800 | 0.87 | MAPT (0.53) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL7857535 | 0.86 | MAPT (0.54) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL329840 | 0.86 | MAPT (0.54) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL7850086 | 0.85 | MAPT (0.51) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL2411970 | 0.85 | MAPT (0.53) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL2411972 | 0.85 | MAPT (0.53) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL10043293 | 0.85 | MAPT (0.53) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL8427720 | 0.84 | MAPT (0.56) | MAPTLONP1PSMB11PSMA7PSMB1 | |
| SCHEMBL13351564 | 0.84 | LONP1 (0.53) | MAPTLONP1PSMB11PSMA7PSMB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-9526769-B2 | Macrocylic oximyl hepatitis C protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2016-12-27 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8940688-B2 | Fluorinated tripeptide HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-01-27 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8785377-B2 | Tetrazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2014-07-22 | — | — | US | disclosed |
| US-8501682-B2 | Difluorinated tripeptides as HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501682-B2 | Difluorinated tripeptides as HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-8361958-B2 | Oximyl HCV serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2013-01-29 | — | — | US | disclosed |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-05-21 | — | — | US | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-08-07 | — | — | US | disclosed |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-07-31 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2007-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090035271-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | MAPT 3832/4885LONP1 128/4885PSMB11 636/4885 |
| US-20080125444-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | MAPT 4533/4885LONP1 121/4885PSMB11 834/4885 |
| US-20080181868-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | MAPT 4388/4885LONP1 161/4885PSMB11 676/4885 |
| US-20070281885-A1 | MACROCYLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | HCCS, CPN1, HPN | MAPT 4388/4885LONP1 161/4885PSMB11 676/4885 |
| US-20090130059-A1 | TETRAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | TMPRSS4, PRSS1, SPINT2 | MAPT 3832/4885LONP1 128/4885PSMB11 636/4885 |
| US-20080187516-A1 | ACYCLIC OXIMYL HEPATITIS C PROTEASE INHIBITORS | CPN1, HPN, HCCS | MAPT 4533/4885LONP1 121/4885PSMB11 834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.